Please login to the form below

Not currently logged in
Email:
Password:

onartuzumab

This page shows the latest onartuzumab news and features for those working in and with pharma, biotech and healthcare.

Deaths cause Amgen to drop stomach cancer drug

Deaths cause Amgen to drop stomach cancer drug

Another drug acting via the HGF/SF:MET pathway - Roche/Genentech's onartuzumab - suffered a setback earlier this year although in this case the problem was a lack of efficacy in

Latest news

  • Roche drug fails in lung cancer trial Roche drug fails in lung cancer trial

    Damages prospects for onartuzumab. A phase III trial of Roche's cancer prospect onartuzumab has been abandoned after the drug failed to show efficacy. ... In a statement, Roche said it is evaluating the implications of the METLung study results across

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics